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S U M M A R Y
Background: The recent H1N1 pandemic virus that emerged in 2009 resulted in high morbidity rates
mainly in younger individuals, albeit with relatively low mortality. We investigated both humoral and
cellular immune responses against the pandemic H1N1 2009 virus before and after immunization with
inactivated H1N1 2009 vaccine.
Methods: We obtained paired blood specimens from a cohort of participants from nursing homes
(n = 108) and a public hospital (n = 60) in Singapore. Serum samples were tested for neutralizing
antibodies against H1N1 2009 using microneutralization assays, while peripheral blood mononuclear
cells were subjected to interferon-g enzyme-linked immunosorbent spot (ELISPOT) assays for whole
virus-speciﬁc T-cell responses.
Results: We observed signiﬁcant increases in geometric mean titers of neutralizing antibodies after
H1N1 2009 vaccination (from 23.6 pre-vaccination to 94.7 post-vaccination). Approximately 77% and
54% of the cohort exhibited 2-fold and 4-fold increases in neutralizing antibody titers following
vaccination; 89.9% of the cohort had a post-vaccination antibody titer of 32. Adjusted for gender,
participants aged 60 years were less likely to have a 4-fold increase in antibody titers after
vaccination than those aged <60 years (0.48; 95% conﬁdence interval (95% CI) 0.32–0.71, p = 0.007).
There was a 1.4-fold elevation in H1N1 2009-speciﬁc T-cell responses after vaccination (p < 0.05).
Adjusted for gender, age 60 years was positively associated with a greater increase in T-cell response
(b = 4.9, 95% CI 1.58–8.29, p = 0.018). No signiﬁcant correlation was observed between humoral and
cellular immune responses.
Conclusions: Inﬂuenza vaccination elicits signiﬁcant neutralizing antibody and T-cell responses to
pandemic H1N1 2009 inﬂuenza virus. However, in response to vaccination, increases in neutralizing
antibody titers were comparatively lower but T-cell responses were higher in older participants.
Therefore, our study suggests that memory T-cells may play a crucial role in protecting older individuals
against pandemic H1N1 2009 infection.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Epidemics caused by inﬂuenza viruses result in the highest
number of vaccine-preventable deaths worldwide annually.
Inﬂuenza viruses have also caused several pandemics in the last
century, including the 1918 H1N1 Spanish ﬂu pandemic that
resulted in up to 40 million deaths, the 1957 H2N2 Asian ﬂu
pandemic with a death toll of 1.5 million worldwide, and the 1968* Corresponding author.
E-mail address: micctk@nus.edu.sg (Vincent T.K. Chow).
1201-9712/$36.00 – see front matter  2012 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2012.04.010H3N2 Hong Kong ﬂu pandemic with about 1 million deaths.1–3
Inﬂuenza pandemics occur when a population with low herd
immunity encounters a newly emerged inﬂuenza virus that can be
transmitted efﬁciently. In April 2009, the World Health Organiza-
tion (WHO) announced the emergence of a novel inﬂuenza that
originated from Mexico and spread around the world. This was
subsequently declared as the ﬁrst inﬂuenza pandemic of the 21st
century in June 2009. The 2009 pandemic inﬂuenza virus (pH1N1
2009) originated from a triple-reassortant virus that had been
circulating in swine during the preceding 10 years.4,5 The
pandemic virus caused a high morbidity rate amongst younger
age groups, but a relatively low overall mortality.6 Pre-existingses. Published by Elsevier Ltd. All rights reserved.
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in elderly individuals over 65 years of age, but none or very low
levels of antibodies were observed in adults and children.7 These
observations could potentially be explained by cross-reactivity
between pandemic H1N1 2009 and older H1N1 strains circulating
before 1950.8,9
Inﬂuenza epidemics and pandemics are usually caused by
antigenic drift and shift, respectively.10 Inﬂuenza vaccines confer
protection by triggering memory B-cells to rapidly produce
antibodies and speciﬁc T-cell responses upon infection.11 Howev-
er, vaccines need to be updated annually to address the antigenic
drift culminating from the high mutation rates of inﬂuenza
viruses.12 In addition, antigenic shift is largely unpredictable,
rendering seasonal inﬂuenza vaccines relatively ineffective for
pandemic inﬂuenza strains. For instance, the 2008–2009 seasonal
inﬂuenza vaccines (inactivated and live, attenuated inﬂuenza
vaccines) were found to induce little or no cross-reactive antibody
responses to pH1N1 2009 in any age group.7 However, the
antibody response is only one aspect of adaptive immunity, since
inﬂuenza virus infection also activates cellular immunity in the
human host. Antibodies are produced by B-cells to neutralize the
virus, while cytotoxic T-cells kill infected cells by binding to
epitopes presented by antigen-presenting cells (APCs).13,14 After
killing cells that present foreign antigens, the immune system will
‘remember’ the infection through memory cells, which will
recognize and react to any future infection by related strains. By
simultaneously measuring both humoral and cellular responses
before and after vaccination, the efﬁcacy of the relatively new
pH1N1 2009 vaccine in triggering these responses during an
infection can be assessed. The objective of this study was to assess
both humoral and cellular responses to pH1N1 2009 vaccination,
identify any differences in pre-existing immunity, and examine the
responses following vaccine challenge by key demographic
characteristics, namely age and gender.
2. Methods
2.1. Study design and sources of samples
Two sets of blood samples were collected from participants, one
prior to pH1N1 2009 vaccination and the other at 4–6 weeks after
vaccination. To include subjects from a wide range of ages, we
recruited consenting participants from four groups of individuals
who were offered pH1N1 2009 vaccination between November 16,
2009 and March 11, 2010. Participants were residents from three
nursing homes in Singapore (Jamiyah Home, Bukit Batok Home,
and Christalite Methodist Home) and healthcare staff of Tan Tock
Seng Hospital, who provided paired samples for the isolation of
serum and peripheral blood mononuclear cells (PBMCs).
Serum samples and PBMCs were then prepared from the blood
samples for the microneutralization assay and the interferon
gamma (IFN-g) enzyme-linked immunosorbent spot (ELISPOT)
assay, respectively. Microneutralization assays were performed to
measure the level of neutralizing antibodies in serum as an
indicator of the humoral immune response. ELISPOT assays were
used to detect the number of spots formed by IFN-g-producing
inﬂuenza-speciﬁc T-cells present within the PBMCs as a measure of
the cellular immune response.
2.2. Processing of serum and PBMC samples
Serum from the test participants was heat-inactivated at 56 8C
for 30 min and stored at 80 8C until use in the microneutraliza-
tion assay. For the isolation of PBMCs, Ficoll-Paque PLUS solution at
a density of 1.077 g/ml (Amersham Biosciences, Uppsala, Sweden)
was used to underlay the whole blood samples, which weresubsequently centrifuged at 900 g at 18–20 8C for 30 min. After
centrifugation, the whole blood was separated into its respective
components, and the buffy coat containing the PBMCs was
extracted. The PBMCs were then washed twice with phosphate-
buffered saline and resuspended in freezing medium comprising
RPMI-1640, 20% fetal bovine serum (FBS), and 10% dimethylsulf-
oxide. PBMC samples were aliquoted and stored at 80 8C until use
in the ELISPOT assays.
2.3. Inﬂuenza virus and vaccine
Inﬂuenza H1N1 A/Singapore/GP2651/2009 virus strain isolated
in Singapore during the H1N1 2009 pandemic was used for both
the microneutralization and ELISPOT assays. This virus is highly
homologous to the vaccine strain, and was propagated in Madin–
Darby canine kidney (MDCK) cells using Eagle’s minimum
essential medium (EMEM). Study participants were immunized
with the Panvax inactivated split H1N1 2009 inﬂuenza vaccine
derived from the A/California/7/2009 (H1N1) virus-like strain
propagated in eggs (CSL, Melbourne, Australia).
2.4. Microneutralization assay
MDCK cells were ﬁrst seeded into 96-well ﬂat bottom plates
and incubated at 37 8C with 5% CO2 for 24 h to obtain conﬂuent
monolayers. Serial two-fold dilutions of each serum sample were
prepared using EMEM as diluent starting with the 1:8 dilution.
Equal volumes of 100 TCID50 (median tissue culture infective dose)
of H1N1 A/Singapore/GP2651/2009 virus were incubated with the
diluted serum samples at 35 8C with 5% CO2 for 2 h.
The cells were washed three times before adding serum-free
medium containing 3 mg/ml of tosyl phenylalanyl chloromethyl
ketone (TPCK)–trypsin, then inoculated with 50 ml of the virus–
serum mixtures and incubated at 35 8C with 5% CO2 for 72 h before
observing for cytopathic effect (CPE) with an inverted microscope
to assess any residual viral replication. The neutralizing antibody
titer was deﬁned as the reciprocal of the highest dilution of the
serum at which the infectivity of 100 TCID50 of the virus for MDCK
cells was completely neutralized in 50% of the wells.8
2.5. IFN-g ELISPOT assay
The secretion of IFN-g was detected by ELISPOT assay.
Multiscreen 96-well plates (Millipore, Billerica, MA, USA) were
coated overnight at 4 8C with 5 mg/ml of anti-human IFN-g capture
antibody (Mabtech, Nacka Strand, Sweden). Plates were blocked
with AIM-V medium (Invitrogen, Carlsbad, CA, USA) supplemented
with 10% FBS for 2 h at room temperature. Cryopreserved PBMCs
were thawed, washed, and added to the plates in triplicate at 105
per well in AIM-V medium supplemented with 2% human serum,
and then incubated at 37 8C for 5 h. Concanavalin A (Sigma-Aldrich,
St. Louis, MO, USA) at 5 mg/ml was included as the positive control
to ensure the viability of the PBMCs tested, while ﬁltered pandemic
H1N1 A/GP2651/2009 strain was added to the test wells at a
multiplicity of infection of 3 before further incubation at 37 8C for
16 h. Plain medium with PBMCs served as negative control.
Medium control wells contained supernatant obtained from ﬂasks
in which H1N1 2009 was passaged in MDCK cells. This was to test
whether the medium would give rise to non-speciﬁc production of
IFN-g.
Plates were washed and incubated for 2 h with 2 mg/ml of
biotinylated anti-IFN-g secondary detection antibody (BD Bios-
ciences, San Jose, CA, USA), followed by 1 h incubation with
streptavidin–horseradish peroxidase enzyme and substrate (BD
Biosciences) at room temperature. 3-Amino-9-ethylcarbazole
(AEC) chromogen in substrate solution (BD Biosciences) was
Table 1
Demographic data of the study cohort.
N = 168 n (%) or mean (SD)
Participant type, No (%)
Bukit Batok Home residents 36 (21.4)
Christalite Methodist Home residents 36 (21.4)
Jamiyah Home residents 36 (21.4)
Tan Tock Seng Hospital staff 60 (35.7)
Gender
Male 80 (47.6)
Female 88 (52.4)
Age group
<60 years 73 (43.5)
60 years 95 (56.5)
Age in years, mean (SD) 58.0 (20.4)
Figure 1. Distribution of pre- and post-vaccination antibodies and T-cell responses
(N = 168). Columns show the proportion of participants; geometric mean titers
(GMT) are indicated below (with 95% conﬁdence intervals as error bars).
(A) Antibody responses as measured by H1N1-speciﬁc neutralizing antibodies.
(B) Interferon-gamma-producing T-cell responses as measured by ELISPOT assays.
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read by an automated ELISPOT reader (Cellular Technology, Shaker
Heights, OH, USA). One spot formed in a well reﬂects one IFN-g-
producing cell, and the size of the spot is proportional to the
amount of IFN-g produced.15,16 Mean spot-forming units (SFU)
were calculated after subtracting the number of spots in the
negative well from the test well. Samples were considered to be
positive for a T-cell response if the number of H1N1-speciﬁc IFN-g-
producing spots was above ﬁve when the negative control was
zero, or at least two times the mean SFU of the negative control
when the negative control was above zero.16,17
2.6. Statistical analyses
For humoral immunity, the geometric mean titer (GMT) and
fold-change were analyzed. For calculation of the GMT, antibody
titers less than 8 were assigned a value of 4, while titers more than
1024 were assigned a value of 2048. The fold-change was then
calculated by dividing the post-vaccination antibody titer by the
pre-vaccination antibody titer. A paired sample t-test was
employed to compare antibody titers and T-cell responses before
and after vaccination. Using the Chi-square test, we assessed if age
and gender were associated with pre-vaccination and post-
vaccination titers 32, as well as with a 4-fold change in
antibody titers (the cut-off neutralizing antibody titer of 32 is
similar to that used in other pH1N1 2009 vaccine studies).18
Univariate and multivariate logistic regression were used, with
robust standard errors computed, the grouping variable being the
respective institutions of the participants.
We compared T-cell responses elicited pre- and post-vaccina-
tion, with the change response being the post-vaccination minus
the pre-vaccination T-cell response. In addition, using the unpaired
sample t-test, we assessed whether age and gender were
associated with pre-vaccination and post-vaccination T-cell
responses. As there are no established cut-off points for T-cell
responses, the relationship between age and gender, pre- and post-
vaccination T-cell ELISPOT responses, and changes in T-cell
ELISPOT values were analyzed on a continuous scale using
multivariate linear regression, again using robust standard errors.
We also utilized Spearman correlation to assess the relationship
between neutralizing antibody titers and T-cell responses. All
statistical analyses were performed using STATA software version
10 (StataCorp, College Station, TX, USA). Standard conﬁdence
intervals, p-value intervals, robust standard errors and associated
p-values in the regression analyses are presented where appropri-
ate. In all analyses, two-tailed p-values of <0.05 were considered to
be statistically signiﬁcant.
3. Results
3.1. Study cohort characteristics
A total of 168 participants were recruited, including 36
residents from each of three nursing homes and 60 staff from
Tan Tock Seng Hospital. Table 1 shows the demographic data for
the study cohort; there were similar numbers of men and women.
The age of participants ranged from 22 to 93 years, with a mean of
58.0 years and median of 64 years. For our regression analyses, we
divided the cohort into two age groups (<60 and 60 years); 56.5%
of participants were aged 60 years.
3.2. Pre- and post-vaccination changes in neutralizing antibody and
T-cell responses
The pre- and post-vaccination H1N1 2009 inﬂuenza-speciﬁc
antibody responses are shown in Figure 1A. More than half (52.4%)of the cohort had a pre-vaccination antibody titer of 32, and this
proportion increased to 89.9% post-vaccination. The geometric
mean titer increased from 23.6 pre-vaccination to 94.7 post-
vaccination (p < 0.001, paired t-test), a mean rise of about 4-fold.
Of the cohort, 53.6% displayed a 4-fold increase, while 77.4%
exhibited a 2-fold increase in neutralizing antibody titers against
the pandemic virus.
The pre- and post-vaccination H1N1 2009-speciﬁc T-cell
responses are shown in Figure 1B. Furthermore, 68.5% of the
participants revealed a positive T-cell response before vaccination.
The mean SFU per 105 PBMCs increased signiﬁcantly from 9.2 SFU
pre-vaccination to 13.8 SFU post-vaccination (p < 0.001, paired t-
test), with an average fold increase of 1.39.
3.3. Differences in neutralizing antibody and T-cell responses by age
and gender
There were signiﬁcant differences in the prevalence of pre- and
post-vaccination neutralizing antibody and T-cell responses, as
Table 2
Differences by age and gender in pre-vaccination, post-vaccination virus neutralization titers and T-cell responses, including changes in antibody titers and T-cell responses.
Microneutralization results, % Mean ELISPOT results, SFU/105 PBMCs (95% CI)
Pre-vaccination
titers 32
Post-vaccination
titers 32
4-fold increase
in titers
Pre-vaccination
response
Post-vaccination
response
Change in response
Age group
<60 years 28.8 82.2 67.1 6.8 (4.0, 9.5) 8.5 (5.4, 11.6) 1.7 (1.3, 4.7)
60 years 70.5 95.8 43.2 11.1 (8.3, 13.8) 17.8 (14.1, 21.5) 6.7 (3.2, 10.2)
p-Value <0.001a 0.004a 0.002a 0.033b <0.001b 0.040b
Gender
Male 65.0 92.5 45.0 11.4 (8.1, 14.6) 18.3 (14.0, 22.6) 6.9 (2.7, 11.1)
Female 40.9 87.5 61.4 7.2 (4.9, 9.6) 9.6 (6.9, 12.4) 2.4 (0.0, 4.8)
p-Value <0.002a 0.283a 0.034a 0.041b <0.001b 0.062b
ELISPOT, enzyme-linked immunosorbent spot assay; SFU, spot-forming units; PBMC, peripheral blood mononuclear cells; CI, conﬁdence interval.
a Chi-square test.
b Unpaired t-test.
J.P. Hsu et al. / International Journal of Infectious Diseases 16 (2012) e621–e627e624well as the change in antibody titers and T-cell responses following
vaccination, between age and gender groups (Table 2). There was a
higher percentage of participants with pre- and post-vaccination
titers of 32 in the older age group compared with the younger age
group (pre-vaccination: 70.5% in those 60 years old vs. 28.8% in
those <60 years old, p < 0.001; post-vaccination: 95.8% vs. 82.2% in
the older vs. younger age group, p = 0.004). On the other hand, a
higher proportion of the younger age group displayed a 4-fold
increase in antibody titer after vaccination compared to the olderFigure 2. Factors associated with neutralizing antibodies and T-cell responses on univari
conﬁdence intervals computed using robust standard errors to account for possible group
and post-vaccination titers 32, and 4-fold increase in titers following vaccination; pre-
every two-fold difference in pre-vaccination titer. (B) Pre- and post-vaccination T-cell
responses as an explanatory variable is modeled on a continuous scale for every 10 SFage group (67.1% vs. 43.2%, p = 0.002). The older age group also
revealed signiﬁcantly higher pre- and post-vaccination T-cell
responses (expressed as SFU per 105 PBMCs) compared to the
younger age group (pre-vaccination: 11.1 vs. 6.8, p = 0.033; post-
vaccination: 17.8 vs. 8.5, p < 0.001). Unlike the antibody responses,
the older age group showed signiﬁcantly greater increases in T-cell
responses after vaccination compared to the younger age group
(6.7 vs. 1.7, p = 0.040). Some gender differences were also
observed, with males having a signiﬁcantly higher prevalence ofate (diamonds) and multivariate (circles) regression analysis. Error bars denote 95%
 level clustering of results, with corresponding p-values provided in the text. (A) Pre-
vaccination titers as an explanatory variable is modeled on a continuous log scale for
 responses, and changes in T-cell response following vaccination; pre-vaccination
U per 105 PBMC difference in pre-vaccination response.
Figure 3. Correlation between humoral and cellular immune responses (N = 168). (A) Pre-vaccination neutralization titers and T-cell responses. (B) Post-vaccination
neutralization titers and T-cell responses. (C) Fold-change in neutralization titers (log scale) and absolute change in T-cell responses. Overlapping data points have been offset
laterally.
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a 4-fold increase in titers, and higher pre- and post-vaccination T-
cell responses.
We assessed the extent that these differences could be
explained by confounding in multivariate regression models. On
multivariate analysis, older age remained signiﬁcantly associated
with higher pre-vaccination titers 32 (adjusted odds ratio (OR)
5.34, p < 0.001) (Figure 2A). However, older age was not associated
with higher post-vaccination titers after accounting for the effect
of higher pre-vaccination titers (adjusted OR 1.80, p = 0.130). On
the other hand, we found that older individuals were still less likely
to exhibit a 4-fold increase in titers (adjusted OR 0.48, p < 0.001),
even after adjusting for the effect from higher pre-vaccination
antibody titers. None of the associations observed with gender
remained signiﬁcant in the multivariate analyses, while pre-
vaccination titers were independently associated with higher post-
vaccination titers and with less likelihood of a 4-fold increase in
titers.
On multivariate regression, older age remained signiﬁcantly
associated both with higher pre- and post-vaccination T-cell
responses (adjusted b = 3.01, p = 0.011, and adjusted b = 4.93,
p = 0.018, respectively), as well as a greater increase in T-cell
responses following vaccination (adjusted b = 4.93, p = 0.018)
(Figure 2B). Females showed signiﬁcantly lower post-vaccination
T-cell responses and a smaller change in T-cell responses following
vaccination. Higher pre-vaccination T-cell responses were also
positively associated with post-vaccination T-cell responses
(adjusted b = 5.67, p = 0.026), but were negatively associated with
the change in T-cell responses (adjusted b = 4.33, p = 0.052).
3.4. Lack of correlation between humoral and cellular immunity to
H1N1 2009
We also examined the correlation between humoral and
cellular immunity to H1N1 2009 as measured by the microneu-
tralization and ELISPOT assays. There was no correlation betweenantibody titers and T-cell responses for either the pre-vaccination
or post-vaccination response (Figure 3A, pre-vaccination: b = 0.81,
p = 0.137, R2 = 0.009; Figure 3B, post-vaccination: b = 0.29,
p = 0.620, R2 = 0.0011). Moreover, there was also no signiﬁcant
correlation between the change in antibody titers and change in T-
cell responses induced by H1N1 2009 vaccination (b = 0.18,
p = 0.803, R2 = 0.0004) (Figure 3C).
4. Discussion
In this study, we simultaneously studied humoral and cellular
immune responses following stimulation with a monovalent
inactivated H1N1 2009 pandemic virus vaccine. The pH1N1
2009 vaccine (Panvax) used in our study was a puriﬁed,
inactivated, monovalent, split virion vaccine containing antigens
of A/California/7/2009 (H1N1-like virus). In concordance with
other vaccine studies,5,19 we found that more than half of the
cohort exhibited a 4-fold increase in antibody titers, with close to
90% achieving neutralization titers of 32 following vaccination.
Compared to live attenuated inﬂuenza vaccines, it is generally
thought that inactivated inﬂuenza vaccines are inefﬁcient in
inducing strong cytotoxic T-cell responses.20,21 Our study revealed
signiﬁcant increases in T-cell responses after vaccination. Howev-
er, there was no concordance between the antibody and T-cell
responses, a result that concurs with a previous ﬁnding in
individuals vaccinated with trivalent inactivated inﬂuenza vaccine
in 2008, suggesting that vaccination does not trigger equivalent
humoral and cellular responses.20,22
Moreover, there were important age-related differences in the
T-cell responses compared to the antibody responses to vaccina-
tion, with older individuals showing both higher pre-vaccination
antibody titers and T-cell responses to pH1N1 2009. The
association between older age and higher pre-vaccination anti-
body titers was documented by Hancock et al.7 The existence of
such cross-reactive antibodies may be explained by prior exposure
to the more closely related H1N1 strains, especially those that
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years when strains antecedent to the H1N1 2009 pandemic were
circulating.11 Furthermore, there is antigenic similarity between
the hemagglutinin (HA) epitopes of pH1N1 1918 and pH1N1 2009
viruses, while antibody obtained from 1918 H1N1 pandemic
survivors has high afﬁnity to pH1N1 2009 viral HA.9 The higher
pre-vaccination T-cell responses could similarly be attributed to
previous exposure to related viruses, so that older individuals are
more likely than younger adults to harbor memory B-cells that
produce cross-reactive antibodies, as well as memory T-cells
capable of recognizing epitopes on the pH1N1 2009 virus.
However, it is interesting that we found that older individuals
were less likely to achieve 4-fold increases in antibody titers than
younger adults, even after adjusting for their higher pre-vaccina-
tion titers which are known to reduce the probability of observing
a further increase in titers,12 while at the same time exhibiting
stronger T-cell responses than younger adults following stimula-
tion with inactivated pH1N1 2009 vaccine.
Previously, others have also observed that older age groups
have a lower likelihood of seroconverting after seasonal inﬂuenza
vaccination,10,23–25 and Woodland and Blackman have postulated
that humoral responses decrease with age.26 However, naı¨ve T-
cell responses decrease with age, so that memory T-cell responses
become the main T-cell responses in the elderly.20We suggest the
following explanation for our ﬁndings. Firstly, the observed
antibody increase is likely due to the vaccine stimulating
predominantly naı¨ve B-cells in both the young and the old, with
the humoral responses being stronger in younger individuals.26
However, because T-cell epitopes are relatively more conserved
than B-cell epitopes,27 the pH1N1 2009 strain on which the
vaccine was based was better able to stimulate memory T-cell
responses compared to memory B-cell responses. Older individu-
als were probably primed with previously circulating H1N1
strains, and hence harbored relevant memory T-cell responses.
The reason why older age was independently associated with the
changes in pre- and post-vaccination T-cell responses may be
attributed to the effect of memory T-cell responses in the older age
group outweighing the naı¨ve T-cell responses in the younger age
group.
The above interpretation of our ﬁndings, if correct, has several
implications both for understanding the epidemiology of pH1N1
2009 inﬂuenza and for the use and design of future seasonal and
pre-pandemic vaccines. Firstly, we suggest that memory T-cells in
particular may be playing a larger role in protecting against
symptomatic infection than is commonly thought.28 This would
explain why older adults had substantially lower symptomatic
infection and seroconversion rates than younger adults, despite
the fact that the majority of these individuals in the community
did not have antibodies to pH1N1 2009 at levels that are
considered protective.29 Secondly, with regards to inﬂuenza
vaccines, there is at least a theoretical concern that the
widespread use of inactivated vaccine formulations that prevent
natural infection but which do not adequately stimulate naı¨ve T-
cell responses in younger individuals may lead to more severe
outcomes in future pandemics, should related inﬂuenza subtypes
be re-introduced into the population (as was the case for pH1N1
2009), particularly since T-cell epitopes tend to be relatively more
conserved.21,27 Given that there is substantial evidence that
individuals who received seasonal inﬂuenza vaccines had an
increased risk of medically attended inﬂuenza during the early
waves of pH1N1 2009 infections, such ﬁndings may also be related
to inadequate T-cell-mediated immunity.30 What is needed
therefore is to further clarify the role of T-cell immunity in
protection against inﬂuenza, possibly through cohort studies
measuring T-cell responses against speciﬁc strains prior to
inﬂuenza outbreaks to see if certain correlates of protection canbe ascertained. Quantifying the role of T-cell immunity in
protecting against inﬂuenza may also yield improved strategies
for the development of pre-pandemic vaccines targeted at
relatively well-conserved T-cell epitopes,19,31 since it is difﬁcult
for pre-pandemic vaccines to be cost-effective without a
reasonably high degree of cross-protection.32
Our study has several limitations. Firstly, our inclusion of the
four groups of participants was opportunistic. Ideally, we would
have liked to have performed the study in groups of individuals
who were similar in all aspects other than age, but we had to
recruit a mix of healthcare staff and residents from long-term
care facilities to assemble a cohort with the range of age groups
necessary for meaningful analyses. Notably, the observed
associations between immunity and gender on univariate
analyses likely resulted from our choice of study population,
since the healthcare staff were largely younger females while
the residents comprised older individuals of both genders. Some
of the observed pre-vaccination immunity may be due to natural
infection with pH1N1 2009 during the epidemic in Singapore
from June to September 2009, although it should be noted that
estimated infection rates in the long-term care facilities and the
healthcare institution included in our study were reasonably
low, i.e. less than 10% in our previous study.29 Secondly, unlike
conventional ELISPOT, the whole virus was used in our
experiments instead of peptides to stimulate the PBMCs.33,34
The use of whole virus in ELISPOT allows us to mimic actual
inﬂuenza infection in vivo, where actively replicating viruses
interact directly with immune cells. Since the objective of this
study was to ascertain whether individuals vaccinated against
pH1N1 2009 were able to generate humoral and cellular
immune responses, we believe this is a valid approach. Due
to the limited quantity of blood sample and PBMC number
obtained from each subject, the CD4 and CD8 T-cell populations
were not analyzed separately. Hence, further studies may be
helpful for distinguishing the contributions of the responses of
the two T-cell subsets, and for identifying the relevant speciﬁc
T-cell epitopes.
In conclusion, our study has revealed that there was a
substantial prevalence of pre-vaccination antibodies as well as
T-cell responses to the pH1N1 2009 virus, particularly in
individuals aged 60 years and above. The pH1N1 2009 vaccine
(Panvax) stimulated both antibody production and the T-cell
response. While we observed no correlation between humoral and
cellular immunity, we found that there were important age-related
differences in the changes observed in humoral and cellular
immunity following vaccination, with individuals born before
1950 having lower seroconversion rates but more robust increases
in T-cell responses. We suggest this may be due to stimulation of
memory T-cells in the elderly, and propose that memory T-cells
may play an important role in affording protection for older
persons against inﬂuenza infections.
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